Lung Cancer Drug Demonstrates Improved Survival in Animal Models

Moleculin’s annamycin significantly improves survival in an aggressive form of triple-negative breast cancer metastasized to the lungs.

 

The anthracycline antibiotic annamycin is a liposome-formulated anthracycline designed to eliminate cardiotoxicity and avoid multidrug resistance mechanisms associated with other approved anthracyclines. It is marketed by Moleculin Biotech and currently being developed by the company as a cancer drug. It was recently granted Fast Track designation by the U.S. Food and Drug Administration for the treatment of patients with relapsed or refractory acute myeloid leukemia.

 

Now Moleculin has even more good news. Researchers at the University of Texas MD Anderson Cancer Center, sponsored by the company, have been investigating the potential of annamycin to treat an aggressive form of triple-negative breast cancer metastasized to the lungs. The scientists demonstrated (https://www.americanpharmaceuticalreview.com/1315-News/360249-Moleculin-Announces-Significant-Discovery-in-Lung-Cancer-Models/) that annamycin, which has been shown to be significantly more potent than doxorubicin in both Lewis lung carcinoma in vivo and small cell lung cancer in vitro models, is also able to significantly improve survival in mouse models for triple-negative breast cancer that has metastasized to the lungs, which is a very aggressive form of cancer.

 

David Alvaro, Ph.D.

David is Scientific Editorial Director for That’s Nice and the Pharma’s Almanac content enterprise, responsible for directing and generating industry, scientific and research-based content, including client-owned strategic content. Before joining That’s Nice, David served as a scientific editor for the multidisciplinary scientific journal Annals of the New York Academy of Sciences. He received a B.A. in Biology from New York University and a Ph.D. in Genetics and Development from Columbia University.